Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy

Table 1 Patient characteristics part I

Pat.No.	Age *	Type of recurrence**	Years after primary disease	Histology primary disease	Histology recurrent disease	Local therapy of primary disease
1	53.9	IBTR	3	lob-inv	lob-inv	BCS + 56 Gy
2	67.2	IBTR	3	duct-inv	duct-inv	BCS + 56 Gy
3	52.1	SBC.	4	duct-inv	aden-cyst	BCS + 62 Gy
4	65.8	SBC	9	lob-inv	duct-inv	BCS + 56 Gy
5	80.7	IBTR	11	lob-inv	lob-inv	BCS + 56 Gy
6	70.6	IBTR	4	duct-inv	duct-inv	BCS + 49 Gy
7	74.1	IBTR	9	lob-inv	lob-inv	BCS + 56 Gy
8	53.9	SBC	13	lob-inv	duct-inv	BCS + 56 Gy
9	48.3	IBTR	14	duct-inv	duct-inv	BCS + 50 Gy
10	75.8	IBTR	17	duct-inv	duct-inv	BCS + 56 Gy
11	78.0	IBIR	10	DCIS	duct-inv	BCS + 56 Gy
12	60.8	IBTR	14	muc-inv	muc-inv	BCS + 56 Gy
13	58.0	IBTR	7	duct-inv	duct-inv	BCS + 56 Gy
14	58.5	IR	10	DCIS	duct-inv	BCS + 56 Gy
15	86.9	IBTR	16	duct-inv	duct-inv	BCS + 56 Gy
16	56,8	BC after Hodgkin	5	nodular	duct-inv	Med 30 Gy
17	66.2	BC after Hodgkin	25	nodular	duct-lob-inv	Med 40 Gy

* Age at time of IBTR, ** Different types of recurrences:
IBTR = In-breast tumour recurrences (which have the same histology and localization)
SBC = Secondary breast cancer (which show a different histology)
IR = Invasive recurrences (after previous DCIS)
BC after Hodgkin = invasive breast cancer after Hodgkin's disease.
Histologies: Duct-inv = ductal-invasive, lob-inv = lobular-invasive, DCIS = Ductal carcinoma in situ, muc-inv = mucinous-invasive, nodular = nodular Hodgkin's disease, duct-lob-inv = mixed histology, partly ductal-invasive, partly lobular-invasive.
Local therapy of primary disease: BCS = breast conserving surgery
Med 30/40 Gy = the two patients with Hodgkin's disease were treated by involved field radiotherapy to the mediastinal lymph nodes with 30/40 Gy respectively.

ISSN: 1471-2407